摘要
目的探讨新型正性肌力药左西孟旦对失代偿期心力衰竭患者心脏功能的改善作用和对血浆N末端脑钠肽前体(NTpro-BNP)水平的影响。方法随机将100例失代偿期心力衰竭患者平均分为常规治疗组(对照组)和左西孟旦+常规治疗组(治疗组)两组各50例。在治疗前和治疗24小时,记录和监测患者呼吸困难评分、心脏功能指标(LVEF、SV、CO和CI值)和血浆NTpro-BNP水平。结果两组患者在给予积极治疗24小时后,呼吸困难评分、心脏功能指标(LVEF、SV、CO和CI值)和血浆NTpro-BNP水平均较治疗前均有明显改善,差异均有统计学意义(均P<0.05)。同时与对照组比较,治疗组呼吸困难评分、心脏功能指标(LVEF、SV、CO和CI值)和血NTpro-BNP水平改善更加显著,差异均有统计学意义(均P<0.05)。研究期间患者均未出现药物相关的严重不良反应。结论新型正性肌力药左西孟旦可以有效地改善失代偿期心力衰竭患者心脏功能和降低血NTpro-BNP水平。
Objective To investigate the effect of levosimendan on heart function and serum level of NTpro-BNP in patients with decompensated heart failure.Methods 100 patients with decompensated heart failure were randomly divided regular treatment group（control group）and levosimendan plus regular treatment group（treatment group）.Before and after 24 htreatments,dyspnea index,heart function indexes（LVEF,SV,CO and CI）and serum level of NTpro-BNP were measured.Results After 24 htreatments,dyspnea index,heart function indexes（LVEF,SV,CO and CI）and serum level of NTpro-BNP were all improved in both two groups（P〈0.05 in all）.Furthermore,comparison with control group,the improvements in treatment group were more significantly（P〈0.05 in all）.Conclusion Levosimendan effectively improved dyspnea index,heart function indexes（LVEF,SV,CO and CI）and serum level of NTpro-BNP in patients with decompensated heart failure.
出处
《西部医学》
2015年第3期387-388,391,共3页
Medical Journal of West China
基金
四川省教育厅课题(11ZB172)
